Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ultragenyx Pharmaceutical Inc. (RARE)
USD33.22
-0.60 (-1.77%)
US NASDAQ Healthcare Biotechnology
Address
60 Leveroni Court 94949
Novato, CA, US
Novato, CA, US
CEO
Emil D. Kakkis
Website
ultragenyx.com
IPO
2014-01-31
CIK 1515673 ISIN US90400D1081
Description
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD33.22
-0.60 (-1.77%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.38
Float Shares
92.93M
Free Float %
94.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.05% | +3.03% | +13.58% | +30.80% | -18.42% | +16.70% | -24.18% | -45.25% | -74.85% | -54.71% | -36.47% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (33 ratings, all time)
Buy
Price Targets & DCF
Current price
33.22
Low
26.00
-21.7%
Consensus
48.36
+45.6%
Median
45.00
+35.5%
High
67.00
+101.7%
Ratings Trend (MoM)
90% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 5 | 0 |
| Buy | 13 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 2 |
55.00
+65.6%
|
| Last Quarter | 8 |
49.00
+47.5%
|
| Last Year | 17 |
50.47
+51.9%
|
| All Time | 42 |
86.71
+161.0%
|
Quality scores
Altman Z-Score
-4.63
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+20.1% ★ Q1'26: -2.4% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+7.3% Q1'26: -17.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-88.4% Q1'26: -145.6% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-79.5% Q1'26: -124.3% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-104.9% Q1'26: -121.1% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+8.9% Q1'26: +4.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-2.55× Q1'26: -1.86× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 14 Rev. Ana. 11 EPS Ana. |
Dec 2027 14 Rev. Ana. 8 EPS Ana. |
Dec 2028 13 Rev. Ana. 8 EPS Ana. |
Dec 2029 12 Rev. Ana. 6 EPS Ana. |
Dec 2030 6 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
133.0K
est: 250.6K (-46.9%)
|
2.61M
est: 611.5K (+327.2%)
|
51.50M
est: 49.01M (+5.1%)
|
103.71M
est: 100.42M (+3.3%)
|
271.03M
est: 250.02M (+8.4%)
|
351.41M
est: 351.78M (-0.1%)
|
363.33M
est: 361.74M (+0.4%)
|
434.25M
est: 481.30M (-9.8%)
|
560.23M
est: 547.60M (+2.3%)
|
673.00M
est: 664.69M (+1.3%)
|
741.94M
726.60M – 764.21M
+11.6% YoY
|
988.07M
741.23M – 1.47B
+33.2% YoY
|
1.23B
1.22B – 1.24B
+24.5% YoY
|
1.62B
1.36B – 2.21B
+32.0% YoY
|
2.13B
1.78B – 2.90B
+31.4% YoY
|
| EBITDA |
-244.58M
est: -234.22M (-4.4%)
|
-312.51M
est: -327.78M (+4.7%)
|
-177.56M
est: -69.36M (-156.0%)
|
-389.77M
est: -367.46M (-6.1%)
|
-139.81M
est: -101.61M (-37.6%)
|
-410.32M
est: -355.54M (-15.4%)
|
-640.49M
est: -375.95M (-70.4%)
|
-516.45M
est: -440.88M (-17.1%)
|
-469.00M
est: -501.61M (+6.5%)
|
-500.00M
est: -608.87M (+17.9%)
|
-679.63M
-700.03M – -665.58M
-11.6% YoY
|
-905.09M
-1.35B – -678.98M
-33.2% YoY
|
-1.13B
-1.14B – -1.11B
-24.5% YoY
|
-1.49B
-2.02B – -1.24B
-32.0% YoY
|
-1.95B
-2.66B – -1.63B
-31.4% YoY
|
| EBIT |
-248.01M
est: -238.75M (-3.9%)
|
-318.34M
est: -337.08M (+5.6%)
|
-197.10M
est: -777.41M (+74.6%)
|
-398.31M
est: -400.33M (+0.5%)
|
-152.07M
est: -515.06M (+70.5%)
|
-423.56M
est: -344.13M (-23.1%)
|
-658.71M
est: -399.22M (-65.0%)
|
-542.46M
est: -452.00M (-20.0%)
|
-504.55M
est: -514.25M (+1.9%)
|
-535.00M
est: -624.21M (+14.3%)
|
-696.76M
-717.68M – -682.36M
-11.6% YoY
|
-927.91M
-1.38B – -696.10M
-33.2% YoY
|
-1.16B
-1.17B – -1.14B
-24.5% YoY
|
-1.52B
-2.07B – -1.27B
-32.0% YoY
|
-2.00B
-2.73B – -1.68B
-31.4% YoY
|
| Net Income |
-245.87M
est: -236.72M (-3.9%)
|
-302.14M
est: -309.44M (+2.4%)
|
-197.61M
est: -115.30M (-71.4%)
|
-402.73M
est: -379.98M (-6.0%)
|
-186.57M
est: -176.32M (-5.8%)
|
-454.03M
est: -396.60M (-14.5%)
|
-707.42M
est: -413.87M (-70.9%)
|
-606.64M
est: -585.12M (-3.7%)
|
-569.18M
est: -612.92M (+7.1%)
|
-575.00M
est: -609.00M (+5.6%)
|
-498.15M
-532.30M – -195.34M
+18.2% YoY
|
-40.12M
-481.68M – 1.06B
+91.9% YoY
|
111.63M
-63.24M – 142.28M
+378.2% YoY
|
286.27M
225.24M – 420.30M
+156.4% YoY
|
530.25M
417.21M – 778.51M
+85.2% YoY
|
| SGA |
64.94M
est: 168.1K (+38,525.5%)
|
99.91M
est: 410.2K (+24,258.5%)
|
127.72M
est: 32.88M (+288.5%)
|
161.52M
est: 67.36M (+139.8%)
|
182.93M
est: 167.71M (+9.1%)
|
219.98M
est: 198.88M (+10.6%)
|
278.14M
est: 215.02M (+29.4%)
|
309.80M
est: 307.80M (+0.6%)
|
321.61M
est: 350.20M (-8.2%)
|
349.00M
est: 425.08M (-17.9%)
|
474.48M
464.68M – 488.73M
+11.6% YoY
|
631.89M
474.03M – 942.09M
+33.2% YoY
|
786.65M
777.30M – 796.00M
+24.5% YoY
|
1.04B
867.96M – 1.41B
+32.0% YoY
|
1.36B
1.14B – 1.86B
+31.4% YoY
|
| EPS |
-6.21
est: -6.14 (-1.1%)
|
-7.12
est: -7.28 (+2.2%)
|
-3.97
est: -4.17 (+4.9%)
|
-7.12
est: -6.94 (-2.6%)
|
-3.07
est: -3.79 (+19.1%)
|
-6.70
est: -6.25 (-7.1%)
|
-10.12
est: -9.92 (-2.0%)
|
-8.25
est: -7.23 (-14.1%)
|
-6.29
est: -6.19 (-1.6%)
|
-5.83
est: -5.60 (-4.1%)
|
-4.49
-5.40 – -1.98
+19.9% YoY
|
-0.65
-4.89 – 10.80
+85.5% YoY
|
0.59
-0.64 – 1.44
+190.2% YoY
|
2.90
2.28 – 4.26
+395.9% YoY
|
5.38
4.23 – 7.90
+85.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-445.84M
OE per share TTM
-4.47
Owner's Yield
-17.09%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
52.5%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
40
Total invested
80.30M
Insider transactions (90d)
10
Beneficial owners (>5%)
26
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Ultragenyx Pharmaceutical Inc. | 7.83M | 14.50% | 7.83M | — | 7.83M | 11.00 | CO | — | 2020-11-06 | ↗ |
| 2 | Capital International Investors ** | 6.59M | 11.40% | 6.31M | — | 6.59M | — | IA | — | 2020-02-14 | ↗ |
| 3 | The Vanguard Group - 23-1945930 | 5.92M | 8.69% | — | 37.4K | 5.83M | 95.3K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 4 | 52-0556948 | 5.68M | 8.10% | 1.84M | — | 5.68M | — | IA | Maryland | 2022-08-10 | ↗ |
| 5 | Wellington Group Holdings LLP | 5.20M | 7.42% | — | 4.80M | — | — | HC | Delaware | 2023-02-06 | ↗ |
| 6 | Wellington Investment Advisors Holdings LLP | 5.20M | 7.42% | — | 4.80M | — | — | HC | Delaware | 2023-02-06 | ↗ |
| 7 | Wellington Management Group LLP | 5.20M | 7.42% | — | 4.80M | — | — | HC | Massachusetts | 2023-02-06 | ↗ |
| 8 | Wellington Management Company LLP | 5.06M | 7.22% | — | 4.78M | — | — | IA | Delaware | 2023-02-06 | ↗ |
| 9 | (1)Names of reporting persons. BlackRock, Inc. | 4.34M | 6.20% | 4.10M | — | 4.34M | — | HC | Delaware | 2023-02-03 | ↗ |
| 10 | Federated Hermes, Inc. | 4.28M | 6.47% | 4.28M | — | 4.28M | — | HC | Citizenship or place of Organization | 2021-02-12 | ↗ |
| 11 | J. Christopher Donahue | 4.28M | 6.47% | — | 4.28M | — | 4.28M | IN | Citizenship or place of Organization | 2021-02-12 | ↗ |
| 12 | Rhodora J. Donahue | 4.28M | 6.47% | — | 4.28M | — | 4.28M | IN | Citizenship or place of Organization | 2021-02-12 | ↗ |
| 13 | Thomas R. Donahue | 4.28M | 6.47% | — | 4.28M | — | 4.28M | IN | Citizenship or place of Organization | 2021-02-12 | ↗ |
| 14 | Voting Shares Irrevocable Trust | 4.28M | 6.47% | 4.28M | — | 4.28M | — | OO | Citizenship or place of Organization | 2021-02-12 | ↗ |
| 15 | Frank M. Sands | 4.12M | 5.00% | — | 2.96M | — | — | HC, IN | United States | 2024-02-13 | ↗ |
| 16 | Sands Capital Management, LLC | 4.12M | 5.00% | — | 2.96M | — | — | IA | Delaware | 2024-02-13 | ↗ |
| 17 | RTW Investments, LP | 3.97M | 5.70% | — | 3.97M | — | — | IA, PN | Delaware | 2023-02-14 | ↗ |
| 18 | Roderick Wong | 3.97M | 5.70% | — | 3.97M | — | — | HC, IN | United States | 2023-02-14 | ↗ |
| 19 | Abigail P. Johnson | 3.81M | 9.00% | — | — | 3.81M | — | IN | Delaware | 2017-07-10 | ↗ |
| 20 | FMR LLC | 3.81M | 9.00% | 435.9K | — | 3.81M | — | HC | Delaware | 2017-07-10 | ↗ |
| 21 | (1) BlackRock, Inc. | 3.41M | 4.90% | 3.24M | — | 3.41M | — | HC | Delaware | 2022-03-09 | ↗ |
| 22 | Capital World Investors ** | 3.24M | 5.60% | 3.24M | — | 3.24M | — | IA | — | 2020-02-14 | ↗ |
| 23 | New Perspective Fund | 2.77M | 6.50% | — | — | — | — | IV | Delaware | 2018-02-14 | ↗ |
| 24 | Susan Jeffs | 1.50M | 8.40% | 82.3K | 1.5K | 2.31M | 82.2K | IN | Pennsylvania | 2016-02-11 | ↗ |
| 25 | 27-2546083 | 1.20M | 4.60% | 1.20M | — | 1.20M | — | CO | — | 2021-10-26 | ↗ |
| 26 | 95-1411037 | 13.00 | 8.30% | 5.58M | — | 5.63M | — | IA | Delaware | 2022-02-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
40
-280 vs prev Q
New positions
11
Closed positions
264
Increased
25
Reduced
8
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 329.1K +329.1K (+100.0%) | 7.57B +7.6B (+100.0%) | 0.33% +0.334 pp | 5.43% +5.426 pp | USD23.00 +0.0% | 1 qtrs NEW |
| 2 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 182.8K +182.8K (+100.0%) | 4.21B +4.2B (+100.0%) | 0.19% +0.185 pp | 0.01% +0.006 pp | USD23.00 +0.0% | 1 qtrs NEW |
| 3 | VANGUARD GROUP INC | 10.26M +131.1K (+1.3%) | 236.07M -68.7M (-22.5%) | 10.41% +0.118 pp | 0.00% -0.001 pp | USD60.30 -61.9% | 48 qtrs — |
| 4 | BLACKROCK, INC. | 6.63M +206.3K (+3.2%) | 152.53M -40.7M (-21.1%) | 6.73% +0.200 pp | 0.00% -0.001 pp | USD52.25 -56.0% | 6 qtrs — |
| 5 | STATE STREET CORP | 4.30M +610.6K (+16.5%) | 98.97M -12.1M (-10.9%) | 4.36% +0.614 pp | 0.00% -0.001 pp | USD45.73 -49.7% | 48 qtrs — |
| 6 | JPMORGAN CHASE & CO | 3.97M -37.4K (-0.9%) | 91.40M -29.3M (-24.3%) | 3.98% -0.091 pp | 0.01% -0.002 pp | USD37.46 -38.6% | 48 qtrs — |
| 7 | SANDS CAPITAL MANAGEMENT, LLC | 3.49M -284.1K (-7.5%) | 80.17M -33.2M (-29.3%) | 3.49% -0.335 pp | 0.24% -0.069 pp | USD45.19 -49.1% | 11 qtrs — |
| 8 | RTW INVESTMENTS, LP | 3.00M -258.1K (-7.9%) | 69.00M -29.0M (-29.6%) | 3.04% -0.267 pp | 0.69% -0.516 pp | USD42.09 -45.4% | 17 qtrs — |
| 9 | BAKER BROS. ADVISORS LP | 2.77M +— (+0.0%) | 63.77M -19.6M (-23.5%) | 2.81% -0.004 pp | 0.37% -0.229 pp | USD55.07 -58.2% | 21 qtrs — |
| 10 | FMR LLC | 2.67M -4.6M (-63.4%) | 61.32M -157.8M (-72.0%) | 2.70% -4.693 pp | 0.00% -0.008 pp | USD33.46 -31.3% | 48 qtrs — |
| 11 | WELLINGTON MANAGEMENT GROUP LLP | 2.46M +516.8K (+26.6%) | 56.62M -1.9M (-3.2%) | 2.50% +0.521 pp | 0.01% 0.000 pp | USD55.26 -58.4% | 48 qtrs — |
| 12 | CITADEL ADVISORS LLC | 2.33M +2.0M (+602.9%) | 53.50M +43.5M (+437.4%) | 2.36% +2.023 pp | 0.01% +0.007 pp | USD24.22 -5.0% | 48 qtrs — |
| 13 | SUVRETTA CAPITAL MANAGEMENT, LLC | 2.02M +— (+0.0%) | 46.44M -14.3M (-23.5%) | 2.05% -0.003 pp | 0.95% -0.603 pp | USD41.40 -44.4% | 17 qtrs — |
| 14 | FRONTIER CAPITAL MANAGEMENT CO LLC | 1.97M +896.0K (+83.8%) | 45.20M +13.0M (+40.5%) | 1.99% +0.907 pp | 0.48% +0.191 pp | USD28.53 -19.4% | 3 qtrs — |
| 15 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 1.90M +354.4K (+22.9%) | 43.69M -2.8M (-6.0%) | 1.93% +0.357 pp | 0.05% -0.070 pp | USD37.46 -38.6% | 9 qtrs — |
| 16 | GEODE CAPITAL MANAGEMENT, LLC | 1.84M +257.7K (+16.3%) | 42.29M -5.3M (-11.1%) | 1.86% +0.259 pp | 0.00% 0.000 pp | USD56.40 -59.2% | 48 qtrs — |
| 17 | MORGAN STANLEY | 1.83M +916.1K (+100.7%) | 42.00M +14.6M (+53.4%) | 1.85% +0.928 pp | 0.00% +0.001 pp | USD35.52 -35.2% | 48 qtrs — |
| 18 | JACOBS LEVY EQUITY MANAGEMENT, INC | 1.75M -418.5K (-19.3%) | 40.23M -25.0M (-38.3%) | 1.77% -0.428 pp | 0.16% -0.104 pp | USD30.96 -25.7% | 3 qtrs — |
| 19 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.55M -755.8K (-32.7%) | 35.75M -33.7M (-48.6%) | 1.58% -0.770 pp | 0.00% -0.004 pp | USD67.66 -66.0% | 48 qtrs — |
| 20 | ABRDN PLC | 1.47M +496.3K (+51.0%) | 33.81M +4.5M (+15.4%) | 1.47% +0.484 pp | 0.05% +0.006 pp | USD31.45 -26.9% | 9 qtrs — |
| 21 | GW&K INVESTMENT MANAGEMENT, LLC | 1.38M +225.2K (+19.6%) | 31.63M -3.0M (-8.6%) | 1.38% +0.210 pp | 0.27% -0.033 pp | USD34.02 -32.4% | 12 qtrs — |
| 22 | AQR CAPITAL MANAGEMENT LLC | 1.36M +614.3K (+82.3%) | 31.29M +8.8M (+39.4%) | 1.38% +0.622 pp | 0.02% +0.002 pp | USD29.30 -21.5% | 9 qtrs — |
| 23 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 1.27M +20.9K (+1.7%) | 29.15M -8.3M (-22.3%) | 1.29% +0.019 pp | 1.49% -0.696 pp | USD58.30 -60.5% | 48 qtrs — |
| 24 | NORGES BANK | 1.26M +1.3M (+100.0%) | 29.00M +29.0M (+100.0%) | 1.26% +1.264 pp | 0.00% +0.003 pp | USD23.00 +0.0% | 1 qtrs NEW |
| 25 | BANK OF AMERICA CORP /DE/ | 1.21M +558.9K (+85.3%) | 27.92M +8.2M (+41.7%) | 1.23% +0.566 pp | 0.00% +0.001 pp | USD36.16 -36.4% | 48 qtrs — |
| 26 | PICTET ASSET MANAGEMENT HOLDING SA | 1.23M -226.9K (-15.6%) | 26.56M -17.4M (-39.6%) | 1.23% -0.247 pp | 0.03% -0.017 pp | USD38.91 -40.9% | 10 qtrs — |
| 27 | JANE STREET GROUP, LLC | 1.02M +667.3K (+188.4%) | 23.49M +12.8M (+120.5%) | 1.04% +0.676 pp | 0.00% +0.002 pp | USD26.52 -13.3% | 26 qtrs — |
| 28 | BNP PARIBAS ARBITRAGE, SNC | 903.1K +330.0K (+57.6%) | 20.77M +3.5M (+20.5%) | 0.92% +0.334 pp | 0.01% +0.000 pp | USD29.95 -23.2% | 46 qtrs — |
| 29 | MILLENNIUM MANAGEMENT LLC | 880.6K +781.4K (+787.6%) | 20.25M +17.3M (+578.7%) | 0.89% +0.792 pp | 0.01% +0.007 pp | USD25.27 -9.0% | 26 qtrs — |
| 30 | RUSSELL INVESTMENTS GROUP, LTD. | 840.8K +369.0 (+0.0%) | 19.34M -5.9M (-23.5%) | 0.85% -0.001 pp | 0.02% -0.008 pp | USD31.39 -26.7% | 37 qtrs — |
| 31 | NUVEEN, LLC | 801.5K +119.3K (+17.5%) | 18.43M -2.1M (-10.2%) | 0.81% +0.120 pp | 0.00% -0.001 pp | USD32.89 -30.1% | 4 qtrs — |
| 32 | CANDRIAM S.C.A. | 799.4K +44.7K (+5.9%) | 18.39M -4.3M (-19.0%) | 0.81% +0.044 pp | 0.09% -0.027 pp | USD42.78 -46.2% | 21 qtrs — |
| 33 | SCHONFELD STRATEGIC ADVISORS LLC | 741.6K -403.0K (-35.2%) | 17.06M -17.4M (-50.5%) | 0.75% -0.410 pp | 0.08% -0.120 pp | USD36.49 -37.0% | 9 qtrs — |
| 34 | UBS GROUP AG | 668.8K +121.8K (+22.3%) | 15.38M -1.1M (-6.5%) | 0.68% +0.123 pp | 0.00% 0.000 pp | USD36.22 -36.5% | 45 qtrs — |
| 35 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 643.4K +160.8K (+33.3%) | 14.80M +281.1K (+1.9%) | 0.65% +0.162 pp | 0.05% +0.003 pp | USD28.31 -18.8% | 2 qtrs — |
| 36 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 631.3K +322.9K (+104.7%) | 14.52M +5.2M (+56.5%) | 0.64% +0.327 pp | 0.00% +0.001 pp | USD31.43 -26.8% | 47 qtrs — |
| 37 | DEUTSCHE BANK AG\ | 599.5K -946.6K (-61.2%) | 13.79M -32.7M (-70.4%) | 0.60% -0.969 pp | 0.00% -0.011 pp | USD49.47 -53.5% | 48 qtrs — |
| 38 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 598.9K -1.2K (-0.2%) | 13.78M -4.3M (-23.7%) | 0.60% -0.009 pp | 0.00% -0.001 pp | USD66.62 -65.5% | 48 qtrs — |
| 39 | POLAR CAPITAL HOLDINGS PLC | 556.6K -27.1K (-4.6%) | 12.80M -4.8M (-27.1%) | 0.56% -0.028 pp | 0.05% -0.035 pp | USD35.87 -35.9% | 4 qtrs — |
| 40 | NORTHERN TRUST CORP | 526.7K +27.5K (+5.5%) | 12.11M -2.9M (-19.3%) | 0.53% +0.027 pp | 0.00% 0.000 pp | USD59.83 -61.6% | 48 qtrs — |
| 41 | BALYASNY ASSET MANAGEMENT L.P. | 520.1K +520.1K (+100.0%) | 11.96M +12.0M (+100.0%) | 0.53% +0.527 pp | 0.02% +0.015 pp | USD23.00 +0.0% | 5 qtrs — |
| 42 | HRT FINANCIAL LP | 501.7K +501.7K (+100.0%) | 11.54M +11.5M (+100.0%) | 0.51% +0.509 pp | 0.04% +0.036 pp | USD23.00 +0.0% | 13 qtrs — |
| 43 | TWO SIGMA ADVISERS, LP | 481.6K -36.1K (-7.0%) | 11.08M -4.5M (-28.9%) | 0.49% -0.037 pp | 0.02% -0.010 pp | USD51.02 -54.9% | 14 qtrs — |
| 44 | JEFFERIES FINANCIAL GROUP INC. | 477.1K +477.1K (+100.0%) | 10.97M +11.0M (+100.0%) | 0.48% +0.478 pp | 0.06% +0.056 pp | USD23.00 +0.0% | 1 qtrs NEW |
| 45 | PALO ALTO INVESTORS LP | 461.3K +91.8K (+24.8%) | 10.61M -505.7K (-4.5%) | 0.47% +0.093 pp | 1.48% -0.580 pp | USD29.34 -21.6% | 3 qtrs — |
| 46 | TWO SIGMA INVESTMENTS, LP | 424.0K +97.9K (+30.0%) | 9.75M -58.4K (-0.6%) | 0.43% +0.099 pp | 0.01% -0.001 pp | USD41.95 -45.2% | 23 qtrs — |
| 47 | FRED ALGER MANAGEMENT, LLC | 411.9K -36.9K (-8.2%) | 9.47M -4.0M (-29.8%) | 0.42% -0.038 pp | 0.04% -0.015 pp | USD52.19 -55.9% | 45 qtrs — |
| 48 | LEGAL & GENERAL GROUP PLC | 411.3K +8.5K (+2.1%) | 9.46M -2.7M (-21.9%) | 0.41% +0.003 pp | 0.00% -0.001 pp | USD39.86 -42.3% | 46 qtrs — |
| 49 | CAPTION MANAGEMENT, LLC | 404.7K +254.9K (+170.2%) | 9.31M +4.8M (+106.6%) | 0.41% +0.258 pp | 0.06% +0.029 pp | USD29.11 -21.0% | 16 qtrs — |
| 50 | MOORE CAPITAL MANAGEMENT, LP | 403.3K +403.3K (+100.0%) | 9.28M +9.3M (+100.0%) | 0.41% +0.409 pp | 0.13% +0.134 pp | USD23.00 +0.0% | 1 qtrs NEW |
| 51 | GOLDMAN SACHS GROUP INC | 400.4K -76.6K (-16.1%) | 9.21M -5.1M (-35.8%) | 0.41% -0.078 pp | 0.00% -0.001 pp | USD48.23 -52.3% | 48 qtrs — |
| 52 | SQUAREPOINT OPS LLC | 390.6K +256.8K (+192.0%) | 8.98M +5.0M (+123.3%) | 0.39% +0.256 pp | 0.01% +0.006 pp | USD25.90 -11.2% | 16 qtrs — |
| 53 | RENAISSANCE TECHNOLOGIES LLC | 366.1K +344.2K (+1,571.7%) | 8.42M +7.8M (+1,178.2%) | 0.37% +0.349 pp | 0.01% +0.012 pp | USD24.58 -6.4% | 6 qtrs — |
| 54 | PRIVIUM FUND MANAGEMENT B.V. | 357.5K +67.7K (+23.4%) | 8.22M -494.8K (-5.7%) | 0.36% +0.064 pp | 1.51% -0.053 pp | USD47.47 -51.5% | 17 qtrs — |
| 55 | SPHERA FUNDS MANAGEMENT LTD. | 350.0K +350.0K (+100.0%) | 8.05M +8.1M (+100.0%) | 0.36% +0.355 pp | 1.56% +1.556 pp | USD23.00 +0.0% | 4 qtrs — |
| 56 | TEACHER RETIREMENT SYSTEM OF TEXAS | 348.4K +327.5K (+1,570.9%) | 8.01M +7.4M (+1,177.6%) | 0.35% +0.328 pp | 0.03% +0.025 pp | USD25.18 -8.7% | 22 qtrs — |
| 57 | D. E. SHAW & CO., INC. | 344.8K +107.1K (+45.1%) | 7.93M +781.3K (+10.9%) | 0.35% +0.108 pp | 0.00% +0.000 pp | USD34.91 -34.1% | 7 qtrs — |
| 58 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 331.2K -13.8K (-4.0%) | 7.61M -2.8M (-26.7%) | 0.33% -0.018 pp | 0.01% -0.002 pp | USD45.23 -49.1% | 16 qtrs — |
| 59 | EVERSEPT PARTNERS, LP | 317.2K +317.2K (+100.0%) | 7.30M +7.3M (+100.0%) | 0.32% +0.322 pp | 0.37% +0.368 pp | USD23.00 +0.0% | 1 qtrs NEW |
| 60 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 310.1K -191.1K (-38.1%) | 7.13M -7.9M (-52.7%) | 0.31% -0.198 pp | 0.00% -0.002 pp | USD48.01 -52.1% | 8 qtrs — |
| 61 | FRANKLIN RESOURCES INC | 309.1K -368.1K (-54.4%) | 7.11M -13.3M (-65.1%) | 0.31% -0.378 pp | 0.00% -0.003 pp | USD37.45 -38.6% | 26 qtrs — |
| 62 | GREAT POINT PARTNERS LLC | 300.0K +300.0K (+100.0%) | 6.90M +6.9M (+100.0%) | 0.30% +0.304 pp | 2.24% +2.237 pp | USD23.00 +0.0% | 1 qtrs NEW |
| 63 | BANK OF NEW YORK MELLON CORP | 298.7K -26.1K (-8.0%) | 6.87M -2.9M (-29.7%) | 0.30% -0.031 pp | 0.00% -0.001 pp | USD56.63 -59.4% | 48 qtrs — |
| 64 | MOTLEY FOOL WEALTH MANAGEMENT, LLC | 297.5K -58.1K (-16.3%) | 6.84M -3.9M (-36.0%) | 0.30% -0.063 pp | 0.53% -0.195 pp | USD45.64 -49.6% | 20 qtrs — |
| 65 | NEWTYN MANAGEMENT, LLC | 295.9K +295.9K (+100.0%) | 6.81M +6.8M (+100.0%) | 0.30% +0.300 pp | 0.72% +0.715 pp | USD23.00 +0.0% | 1 qtrs NEW |
| 66 | VERITION FUND MANAGEMENT LLC | 282.4K +258.9K (+1,100.6%) | 6.49M +5.8M (+818.0%) | 0.28% +0.259 pp | 0.03% +0.023 pp | USD24.63 -6.6% | 16 qtrs — |
| 67 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 280.0K -150.0K (-34.9%) | 6.44M -6.5M (-50.2%) | 0.28% -0.153 pp | 0.01% -0.011 pp | USD41.62 -44.7% | 21 qtrs — |
| 68 | AMERIPRISE FINANCIAL INC | 276.9K +138.2K (+99.7%) | 6.37M +2.2M (+52.7%) | 0.28% +0.140 pp | 0.00% +0.001 pp | USD29.81 -22.8% | 48 qtrs — |
| 69 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 263.9K +184.9K (+234.3%) | 6.07M +3.7M (+155.6%) | 0.26% +0.184 pp | 0.02% +0.008 pp | USD25.38 -9.4% | 15 qtrs — |
| 70 | ENSIGN PEAK ADVISORS, INC | 250.6K +73.2K (+41.2%) | 5.76M +426.3K (+8.0%) | 0.25% +0.071 pp | 0.01% +0.001 pp | USD31.44 -26.8% | 17 qtrs — |
| 71 | IKARIAN CAPITAL, LLC | 250.0K +250.0K (+100.0%) | 5.75M +5.8M (+100.0%) | 0.25% +0.254 pp | 0.45% +0.449 pp | USD23.00 +0.0% | 4 qtrs — |
| 72 | INVESCO LTD. | 230.3K -564.6K (-71.0%) | 5.30M -18.6M (-77.8%) | 0.23% -0.574 pp | 0.00% -0.003 pp | USD46.43 -50.5% | 38 qtrs — |
| 73 | 683 CAPITAL MANAGEMENT, LLC | 222.4K +116.4K (+109.8%) | 5.12M +1.9M (+60.4%) | 0.23% +0.118 pp | 0.22% +0.056 pp | USD26.37 -12.8% | 2 qtrs — |
| 74 | ALGERT GLOBAL LLC | 219.2K -102.4K (-31.8%) | 5.04M -4.6M (-47.9%) | 0.22% -0.104 pp | 0.08% -0.083 pp | USD34.38 -33.1% | 12 qtrs — |
| 75 | BLUE OWL CAPITAL HOLDINGS LP | 212.6K -209.8K (-49.7%) | 4.89M -7.8M (-61.5%) | 0.22% -0.213 pp | 0.37% -3.579 pp | USD37.07 -38.0% | 9 qtrs — |
| 76 | EMERALD ADVISERS, LLC | 212.4K -206.2K (-49.3%) | 4.88M -7.7M (-61.2%) | 0.21% -0.212 pp | 0.15% -0.253 pp | USD70.48 -67.4% | 21 qtrs — |
| 77 | UBS ASSET MANAGEMENT AMERICAS INC | 204.1K -2.9K (-1.4%) | 4.69M -1.5M (-24.6%) | 0.20% -0.006 pp | 0.00% 0.000 pp | USD49.95 -54.0% | 45 qtrs — |
| 78 | BARCLAYS PLC | 200.0K +— (+0.0%) | 4.60M -1.4M (-23.5%) | 0.20% 0.000 pp | 0.00% 0.000 pp | USD36.34 -36.7% | 4 qtrs — |
| 79 | ASSENAGON ASSET MANAGEMENT S.A. | 199.7K -52.9K (-21.0%) | 4.59M -3.0M (-39.6%) | 0.20% -0.056 pp | 0.01% -0.004 pp | USD36.64 -37.2% | 18 qtrs — |
| 80 | FISHER ASSET MANAGEMENT, LLC | 198.7K +30.6K (+18.2%) | 4.57M -486.0K (-9.6%) | 0.20% +0.028 pp | 0.00% 0.000 pp | USD39.13 -41.2% | 5 qtrs — |
| 81 | PDT PARTNERS, LLC | 176.8K +20.1K (+12.8%) | 4.07M -646.6K (-13.7%) | 0.18% +0.020 pp | 0.26% -0.033 pp | USD38.15 -39.7% | 11 qtrs — |
| 82 | SCHRODER INVESTMENT MANAGEMENT GROUP | 175.6K +25.1K (+16.6%) | 4.00M -570.4K (-12.5%) | 0.18% +0.025 pp | 0.00% -0.001 pp | USD39.55 -41.8% | 9 qtrs — |
| 83 | WOODLINE PARTNERS LP | 171.8K -101.4K (-37.1%) | 3.95M -4.3M (-51.9%) | 0.17% -0.103 pp | 0.02% -0.023 pp | USD46.75 -50.8% | 11 qtrs — |
| 84 | SWISS NATIONAL BANK | 171.1K +6.1K (+3.7%) | 3.93M -1.0M (-20.7%) | 0.17% +0.004 pp | 0.00% -0.001 pp | USD61.86 -62.8% | 47 qtrs — |
| 85 | TREXQUANT INVESTMENT LP | 165.0K +9.6K (+6.2%) | 3.80M -878.7K (-18.8%) | 0.17% +0.010 pp | 0.03% -0.014 pp | USD45.76 -49.7% | 16 qtrs — |
| 86 | ROYAL BANK OF CANADA | 163.2K -73.1K (-30.9%) | 3.75M -3.4M (-47.2%) | 0.17% -0.074 pp | 0.00% -0.001 pp | USD30.78 -25.3% | 44 qtrs — |
| 87 | CATALIO CAPITAL MANAGEMENT, LP | 162.6K -128.7K (-44.2%) | 3.74M -5.0M (-57.3%) | 0.16% -0.131 pp | 0.66% -0.959 pp | USD34.68 -33.7% | 3 qtrs — |
| 88 | WCM INVESTMENT MANAGEMENT, LLC | 163.3K -124.8K (-43.3%) | 3.72M -5.0M (-57.5%) | 0.16% -0.129 pp | 0.01% -0.011 pp | USD41.99 -45.2% | 24 qtrs — |
| 89 | RAFFERTY ASSET MANAGEMENT, LLC | 157.1K +577.0 (+0.4%) | 3.61M -1.1M (-23.3%) | 0.16% +0.000 pp | 0.01% -0.003 pp | USD43.44 -47.1% | 28 qtrs — |
| 90 | SEI INVESTMENTS CO | 153.7K -36.7K (-19.3%) | 3.54M -2.2M (-38.3%) | 0.15% -0.039 pp | 0.00% -0.003 pp | USD39.09 -41.2% | 17 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
5.33
Bullish
Ratio by volume
3.00
Bullish
Buys
16
Sells
3
Shares acquired
790.1K
Shares disposed
9.7K
Cash buys
—
Cash sales
3.00
Net activity
+780,383
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | Crombez Eric | Officer | S-Sale | D | Common Stock | 344 | 24.96 | 8.6K | 111,189 | D | ↗ |
| 2026-05-01 | Horn Howard | Officer | S-Sale | D | Common Stock | 4,683 | 24.90 | 116.6K | 110,342 | D | ↗ |
| 2026-04-22 | Huizenga Theodore Alan | Officer | A-Award | A | Common Stock | 20,241 | 0.00 | — | 68,911 | D | ↗ |
| 2026-04-16 | Pinion John Richard | Officer | A-Award | A | Stock Option (Right to Buy) | 79,936 | 24.52 | 1.96M | 79,936 | D | ↗ |
| 2026-04-16 | Parschauer Karah Herdman | Officer | A-Award | A | Common Stock | 28,895 | 0.00 | — | 95,715 | D | ↗ |
| 2026-04-16 | KAKKIS EMIL D | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 132,693 | 24.52 | 3.25M | 132,693 | D | ↗ |
| 2026-04-16 | Huang Dennis Karl | Officer | A-Award | A | Stock Option (Right to Buy) | 79,936 | 24.52 | 1.96M | 79,936 | D | ↗ |
| 2026-04-16 | Horn Howard | Officer | A-Award | A | Stock Option (Right to Buy) | 59,952 | 24.52 | 1.47M | 59,952 | D | ↗ |
| 2026-04-16 | Harris Erik | Officer | A-Award | A | Stock Option (Right to Buy) | 49,960 | 24.52 | 1.23M | 49,960 | D | ↗ |
| 2026-04-16 | Crombez Eric | Officer | A-Award | A | Common Stock | 34,674 | 0.00 | — | 110,975 | D | ↗ |
| 2026-04-01 | Horn Howard | Officer | S-Sale | D | Common Stock | 4,683 | 20.97 | 98.2K | 80,351 | D | ↗ |
| 2026-03-10 | Parschauer Karah Herdman | Officer | S-Sale | D | Common Stock | 3,508 | 22.67 | 79.5K | 66,820 | D | ↗ |
| 2026-03-06 | Parschauer Karah Herdman | Officer | S-Sale | D | Common Stock | 6,018 | 21.40 | 128.8K | 70,328 | D | ↗ |
| 2026-03-03 | Horn Howard | Officer | S-Sale | D | Common Stock | 1,635 | 22.40 | 36.6K | 85,034 | D | ↗ |
| 2026-03-02 | Pinion John Richard | Officer | S-Sale | D | Common Stock | 10,029 | 22.80 | 228.7K | 110,026 | D | ↗ |
| 2026-03-02 | Parschauer Karah Herdman | Officer | S-Sale | D | Common Stock | 8,135 | 22.80 | 185.5K | 76,346 | D | ↗ |
| 2026-03-02 | KAKKIS EMIL D | Director / Officer | S-Sale | D | Common Stock | 54,404 | 22.80 | 1.24M | 658,994 | D | ↗ |
| 2026-03-02 | Huizenga Theodore Alan | Officer | S-Sale | D | Common Stock | 1,632 | 22.80 | 37.2K | 48,670 | D | ↗ |
| 2026-03-02 | Huang Dennis Karl | Officer | F-InKind | D | Common Stock | 999 | 23.39 | 23.4K | 124,729 | D | ↗ |
| 2026-03-02 | Horn Howard | Officer | S-Sale | D | Common Stock | 5,290 | 22.80 | 120.6K | 89,788 | D | ↗ |
| 2026-03-02 | Harris Erik | Officer | S-Sale | D | Common Stock | 10,539 | 22.80 | 240.3K | 89,515 | D | ↗ |
| 2026-03-02 | Crombez Eric | Officer | S-Sale | D | Common Stock | 7,029 | 22.80 | 160.3K | 76,301 | D | ↗ |
| 2026-03-01 | Pinion John Richard | Officer | A-Award | A | Common Stock | 11,137 | 0.00 | — | 119,565 | D | ↗ |
| 2026-03-01 | Parschauer Karah Herdman | Officer | A-Award | A | Common Stock | 11,137 | 0.00 | — | 84,408 | D | ↗ |
| 2026-03-01 | KAKKIS EMIL D | Director / Officer | A-Award | A | Common Stock | 71,177 | 0.00 | — | 712,908 | D | ↗ |
| 2026-03-01 | Huang Dennis Karl | Officer | A-Award | A | Common Stock | 11,137 | 0.00 | — | 125,728 | D | ↗ |
| 2026-03-01 | Horn Howard | Officer | A-Award | A | Common Stock | 6,143 | 0.00 | — | 95,078 | D | ↗ |
| 2026-03-01 | Harris Erik | Officer | A-Award | A | Common Stock | 11,643 | 0.00 | — | 99,498 | D | ↗ |
| 2026-03-01 | Crombez Eric | Officer | A-Award | A | Common Stock | 11,643 | 0.00 | — | 83,173 | D | ↗ |
| 2026-02-02 | Horn Howard | Officer | S-Sale | D | Common Stock | 3,061 | 23.56 | 72.1K | 88,935 | D | ↗ |
| 2026-01-02 | Horn Howard | Officer | S-Sale | D | Common Stock | 3,150 | 22.84 | 71.9K | 91,996 | D | ↗ |
| 2025-12-29 | Huizenga Theodore Alan | Officer | S-Sale | D | Common Stock | 85 | 34.38 | 2.9K | 50,450 | D | ↗ |
| 2025-12-10 | Horn Howard | Officer | S-Sale | D | Common Stock | 3,081 | 36.38 | 112.1K | 95,146 | D | ↗ |
| 2025-10-13 | Horn Howard | Officer | S-Sale | D | Common Stock | 7,942 | 31.51 | 250.3K | 98,227 | D | ↗ |
| 2025-09-18 | Huizenga Theodore Alan | Officer | S-Sale | D | Common Stock | 64 | 29.17 | 1.9K | 50,242 | D | ↗ |
| 2025-09-12 | Parschauer Karah Herdman | Officer | S-Sale | D | Common Stock | 2,450 | 31.17 | 76.4K | 73,271 | D | ↗ |
| 2025-09-05 | Huizenga Theodore Alan | Officer | S-Sale | D | Common Stock | 84 | 31.39 | 2.6K | 50,306 | D | ↗ |
| 2025-06-20 | Sanders Corazon (Corsee) D. | Director | S-Sale | D | Common Stock | 2,405 | 37.39 | 89.9K | 15,344 | D | ↗ |
| 2025-05-15 | WELCH DANIEL G | Director | A-Award | A | Stock Option (Right to Buy) | 10,787 | 34.84 | 375.8K | 10,787 | D | ↗ |
| 2025-05-15 | Sanders Corazon (Corsee) D. | Director | A-Award | A | Common Stock | 5,740 | 0.00 | — | 17,749 | D | ↗ |
| 2025-05-15 | SULIMAN SHEHNAAZ | Director | A-Award | A | Stock Option (Right to Buy) | 10,787 | 34.84 | 375.8K | 10,787 | D | ↗ |
| 2025-05-15 | Ray Amrit | Director | A-Award | A | Common Stock | 5,740 | 0.00 | — | 23,365 | D | ↗ |
| 2025-05-15 | NARACHI MICHAEL | Director | A-Award | A | Stock Option (Right to Buy) | 10,787 | 34.84 | 375.8K | 10,787 | D | ↗ |
| 2025-05-15 | Fust Matthew K | Director | A-Award | A | Stock Option (Right to Buy) | 10,787 | 34.84 | 375.8K | 10,787 | D | ↗ |
| 2025-05-15 | Dunsire Deborah | Director | A-Award | A | Stock Option (Right to Buy) | 10,787 | 34.84 | 375.8K | 10,787 | D | ↗ |
| 2025-05-05 | Crombez Eric | Officer | S-Sale | D | Common Stock | 520 | 39.24 | 20.4K | 71,530 | D | ↗ |
| 2025-04-21 | Crombez Eric | Officer | S-Sale | D | Common Stock | 242 | 35.11 | 8.5K | 71,680 | D | ↗ |
| 2025-03-06 | Horn Howard | Officer | S-Sale | D | Common Stock | 1,785 | 40.40 | 72.1K | 106,169 | D | ↗ |
| 2025-03-03 | Pinion John Richard | Officer | S-Sale | D | Common Stock | 14,439 | 42.10 | 607.9K | 107,766 | D | ↗ |
| 2025-03-03 | Parschauer Karah Herdman | Officer | S-Sale | D | Common Stock | 12,846 | 42.10 | 540.8K | 75,287 | D | ↗ |
| 2025-03-03 | Kassberg Thomas Richard | Officer | S-Sale | D | Common Stock | 6,028 | 42.10 | 253.8K | 265,238 | D | ↗ |
| 2025-03-03 | KAKKIS EMIL D | Director / Officer | S-Sale | D | Common Stock | 73,434 | 42.10 | 3.09M | 641,731 | D | ↗ |
| 2025-03-03 | Huizenga Theodore Alan | Officer | F-InKind | D | Common Stock | 141 | 42.92 | 6.1K | 50,124 | D | ↗ |
| 2025-03-03 | Huang Dennis Karl | Officer | F-InKind | D | Common Stock | 1,348 | 42.92 | 57.9K | 114,591 | D | ↗ |
| 2025-03-03 | Harris Erik | Officer | S-Sale | D | Common Stock | 15,103 | 42.10 | 635.8K | 87,855 | D | ↗ |
| 2025-03-03 | Crombez Eric | Officer | S-Sale | D | Common Stock | 8,945 | 42.10 | 376.6K | 71,922 | D | ↗ |
| 2025-03-01 | Pinion John Richard | Officer | A-Award | A | Common Stock | 18,443 | 0.00 | — | 122,205 | D | ↗ |
| 2025-03-01 | Parschauer Karah Herdman | Officer | A-Award | A | Stock Option (Right to Buy) | 26,074 | 42.92 | 1.12M | 26,074 | D | ↗ |
| 2025-03-01 | Kassberg Thomas Richard | Officer | A-Award | A | Common Stock | 18,443 | 0.00 | — | 271,266 | D | ↗ |
| 2025-03-01 | KAKKIS EMIL D | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 78,448 | 42.92 | 3.37M | 78,448 | D | ↗ |
| 2025-03-01 | Huizenga Theodore Alan | Officer | A-Award | A | Common Stock | 9,392 | 0.00 | — | 51,232 | D | ↗ |
| 2025-03-01 | Huang Dennis Karl | Officer | A-Award | A | Stock Option (Right to Buy) | 26,074 | 42.92 | 1.12M | 26,074 | D | ↗ |
| 2025-03-01 | Horn Howard | Officer | A-Award | A | Stock Option (Right to Buy) | 28,160 | 42.92 | 1.21M | 28,160 | D | ↗ |
| 2025-03-01 | Harris Erik | Officer | A-Award | A | Stock Option (Right to Buy) | 30,246 | 42.92 | 1.30M | 30,246 | D | ↗ |
| 2025-03-01 | Crombez Eric | Officer | A-Award | A | Common Stock | 16,813 | 0.00 | — | 65,244 | D | ↗ |
| 2025-02-28 | KAKKIS EMIL D | Director / Officer | S-Sale | D | Common Stock | 25,000 | 42.48 | 1.06M | 2,158,985 | I | ↗ |
| 2025-02-27 | Parschauer Karah Herdman | Officer | S-Sale | D | Common Stock | 2,230 | 42.93 | 95.7K | 55,751 | D | ↗ |
| 2024-12-30 | KAKKIS EMIL D | Director / Officer | S-Sale | D | Common Stock | 11,727 | 42.23 | 495.2K | 2,183,985 | I | ↗ |
| 2024-12-10 | KAKKIS EMIL D | Director / Officer | S-Sale | D | Common Stock | 8,273 | 50.00 | 413.7K | 2,195,712 | I | ↗ |
| 2024-12-10 | Huizenga Theodore Alan | Officer | G-Gift | D | Common Stock | 648 | 0.00 | — | 41,840 | D | ↗ |
| 2024-12-09 | KAKKIS EMIL D | Director / Officer | G-Gift | D | Common Stock | 20,000 | 0.00 | — | 2,203,985 | I | ↗ |
| 2024-10-10 | Horn Howard | Officer | S-Sale | D | Common Stock | 7,465 | 52.76 | 393.9K | 92,301 | D | ↗ |
| 2024-09-16 | Huizenga Theodore Alan | Officer | A-Award | A | Common Stock | 700 | 0.00 | — | 42,251 | — | ↗ |
| 2024-09-03 | KAKKIS EMIL D | Director / Officer | S-Sale | D | Common Stock | 20,000 | 55.85 | 1.12M | 2,223,985 | — | ↗ |
| 2024-09-03 | Huizenga Theodore Alan | Officer | S-Sale | D | Common Stock | 91 | 56.19 | 5.1K | 41,551 | — | ↗ |
| 2024-08-06 | KAKKIS EMIL D | Director / Officer | S-Sale | D | Common Stock | 20,000 | 50.17 | 1.00M | 2,243,985 | — | ↗ |
| 2024-07-02 | Sanders Corazon (Corsee) D. | Director | S-Sale | D | Common Stock | 584 | 40.98 | 23.9K | 12,009 | — | ↗ |
| 2024-06-18 | WELCH DANIEL G | Director | A-Award | A | Common Stock | 5,345 | 0.00 | — | 26,950 | — | ↗ |
| 2024-06-18 | Sanders Corazon (Corsee) D. | Director | A-Award | A | Stock Option (Right to Buy) | 9,900 | 37.42 | 370.5K | 9,900 | — | ↗ |
| 2024-06-18 | SULIMAN SHEHNAAZ | Director | A-Award | A | Stock Option (Right to Buy) | 9,900 | 37.42 | 370.5K | 9,900 | — | ↗ |
| 2024-06-18 | Ray Amrit | Director | A-Award | A | Stock Option (Right to Buy) | 9,900 | 37.42 | 370.5K | 9,900 | — | ↗ |
| 2024-06-18 | NARACHI MICHAEL | Director | A-Award | A | Stock Option (Right to Buy) | 9,900 | 37.42 | 370.5K | 9,900 | — | ↗ |
| 2024-06-18 | Fust Matthew K | Director | A-Award | A | Stock Option (Right to Buy) | 9,900 | 37.42 | 370.5K | 9,900 | — | ↗ |
| 2024-06-18 | Dunsire Deborah | Director | A-Award | A | Common Stock | 5,345 | 0.00 | — | 25,075 | — | ↗ |
| 2024-06-12 | Parschauer Karah Herdman | Officer | S-Sale | D | Common Stock | 9,806 | 45.00 | 441.3K | 57,981 | — | ↗ |
| 2024-06-10 | Sanders Corazon (Corsee) D. | Director | S-Sale | D | Common Stock | 1,737 | 41.10 | 71.4K | 7,248 | — | ↗ |
| 2024-05-02 | Crombez Eric | Officer | S-Sale | D | Common Stock | 354 | 43.66 | 15.5K | 48,431 | — | ↗ |
| 2024-04-18 | Crombez Eric | Officer | S-Sale | D | Common Stock | 142 | 44.10 | 6.3K | 48,785 | — | ↗ |
| 2024-04-16 | Huizenga Theodore Alan | Officer | F-InKind | D | Common Stock | 14 | 42.31 | 592.34 | 41,366 | — | ↗ |
| 2024-03-11 | Kassberg Thomas Richard | Officer | S-Sale | D | Common Stock | 11,509 | 49.93 | 574.6K | 252,823 | — | ↗ |
| 2024-03-07 | Fust Matthew K | Director | S-Sale | D | Common Stock | 2,550 | 50.89 | 129.8K | 24,505 | — | ↗ |
| 2024-03-01 | Pinion John Richard | Officer | S-Sale | D | Common Stock | 4,173 | 53.76 | 224.3K | 89,268 | — | ↗ |
| 2024-03-01 | Parschauer Karah Herdman | Officer | A-Award | A | Common Stock | 957 | 0.00 | — | 70,739 | — | ↗ |
| 2024-03-01 | Kassberg Thomas Richard | Officer | F-InKind | D | Common Stock | 274 | 53.69 | 14.7K | 265,343 | — | ↗ |
| 2024-03-01 | KAKKIS EMIL D | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 70,094 | 53.69 | 3.76M | 70,094 | — | ↗ |
| 2024-03-01 | Huizenga Theodore Alan | Officer | A-Award | A | Common Stock | 13,950 | 0.00 | — | 41,842 | — | ↗ |
| 2024-03-01 | Huang Dennis Karl | Officer | A-Award | A | Common Stock | 957 | 0.00 | — | 83,472 | — | ↗ |
| 2024-03-01 | Horn Howard | Officer | A-Award | A | Common Stock | 19,400 | 0.00 | — | 99,766 | — | ↗ |
| 2024-03-01 | Harris Erik | Officer | A-Award | A | Common Stock | 957 | 0.00 | — | 71,638 | — | ↗ |
| 2024-03-01 | Crombez Eric | Officer | A-Award | A | Stock Option (Right to Buy) | 34,200 | 53.69 | 1.84M | 34,200 | — | ↗ |
| 2024-02-07 | KAKKIS EMIL D | Director / Officer | S-Sale | D | Common Stock | 30,000 | 45.00 | 1.35M | 539,770 | — | ↗ |
| 2024-01-02 | Huizenga Theodore Alan | Officer | M-Exempt | A | Common Stock | 3,000 | 21.00 | 63.0K | 27,892 | — | ↗ |
| 2023-12-29 | KAKKIS EMIL D | Director / Officer | S-Sale | D | Common Stock | 30,000 | 47.87 | 1.44M | 569,770 | — | ↗ |
| 2023-12-20 | Huizenga Theodore Alan | Officer | A-Award | A | Common Stock | 1,000 | 0.00 | — | 24,614 | — | ↗ |
| 2023-10-23 | Kassberg Thomas Richard | Officer | S-Sale | D | Common Stock | 39,878 | 32.78 | 1.31M | 246,860 | — | ↗ |
| 2023-10-19 | KAKKIS EMIL D | Director / Officer | M-Exempt | A | Common Stock | 47,853 | 6.86 | 328.3K | 647,029 | — | ↗ |
| 2023-10-09 | Horn Howard | Officer | A-Award | A | Stock Option (Right to Buy) | 140,469 | 35.68 | 5.01M | 140,469 | — | ↗ |
| 2023-09-27 | Huizenga Theodore Alan | Officer | A-Award | A | Stock Option (Right to Buy) | 2,351 | 67.37 | 158.4K | 2,351 | — | ↗ |
| 2023-09-27 | Crombez Eric | Officer | A-Award | A | Stock Option (Right to Buy) | 2,351 | 67.37 | 158.4K | 2,351 | — | ↗ |
| 2023-09-07 | Huizenga Theodore Alan | Officer | S-Sale | D | Common Stock | 2,000 | 41.00 | 82.0K | 23,777 | — | ↗ |
| 2023-09-05 | Harris Erik | Officer | S-Sale | D | Common Stock | 6,000 | 37.96 | 227.8K | 51,281 | — | ↗ |
| 2023-09-01 | Huizenga Theodore Alan | Officer | S-Sale | D | Common Stock | 883 | 37.04 | 32.7K | 23,864 | — | ↗ |
| 2023-06-30 | Sanders Corazon (Corsee) D. | Director | S-Sale | D | Common Stock | 585 | 46.76 | 27.4K | 8,985 | — | ↗ |
| 2023-06-19 | Harris Erik | Officer | S-Sale | D | Common Stock | 305 | 48.20 | 14.7K | 57,281 | — | ↗ |
| 2023-06-08 | Sanders Corazon (Corsee) D. | Director | S-Sale | D | Common Stock | 1,485 | 51.65 | 76.7K | 9,570 | — | ↗ |
| 2023-06-07 | WELCH DANIEL G | Director | A-Award | A | Stock Option (Right to Buy) | 7,110 | 51.82 | 368.4K | 7,110 | — | ↗ |
| 2023-06-07 | Sanders Corazon (Corsee) D. | Director | A-Award | A | Stock Option (Right to Buy) | 7,110 | 51.82 | 368.4K | 7,110 | — | ↗ |
| 2023-06-07 | SULIMAN SHEHNAAZ | Director | A-Award | A | Common Stock | 3,860 | 0.00 | — | 14,855 | — | ↗ |
| 2023-06-07 | Ray Amrit | Director | A-Award | A | Stock Option (Right to Buy) | 7,110 | 51.82 | 368.4K | 7,110 | — | ↗ |
| 2023-06-07 | NARACHI MICHAEL | Director | A-Award | A | Common Stock | 7,110 | 51.82 | 368.4K | 7,110 | — | ↗ |
| 2023-06-07 | Fust Matthew K | Director | A-Award | A | Stock Option (Right to Buy) | 7,110 | 51.82 | 368.4K | 7,110 | — | ↗ |
| 2023-06-07 | Dunsire Deborah | Director | A-Award | A | Stock Option (Right to Buy) | 7,110 | 51.82 | 368.4K | 7,110 | — | ↗ |
| 2023-05-18 | Pinion John Richard | Officer | S-Sale | D | Common Stock | 2,012 | 50.00 | 100.6K | 74,744 | — | ↗ |
| 2023-05-09 | Huizenga Theodore Alan | Officer | M-Exempt | A | Common Stock | 3,000 | 21.00 | 63.0K | 30,747 | — | ↗ |
| 2023-05-04 | Parschauer Karah Herdman | Officer | S-Sale | D | Common Stock | 4,378 | 45.00 | 197.0K | 51,982 | — | ↗ |
| 2023-05-01 | Crombez Eric | Officer | — | D | Stock Option (Right to Buy) | 8,000 | 67.55 | 540.4K | 0 | — | ↗ |
| 2023-04-16 | Huizenga Theodore Alan | Officer | F-InKind | D | Common Stock | 14 | 38.20 | 534.80 | 27,701 | — | ↗ |
| 2023-03-01 | Pinion John Richard | Officer | A-Award | A | 3/1/2023 | 39,400 | 45.65 | 1.80M | 39,400 | — | ↗ |
| 2023-03-01 | Parschauer Karah Herdman | Officer | A-Award | A | Common Stock | 2,663 | 0.00 | — | 37,101 | — | ↗ |
| 2023-03-01 | Kassberg Thomas Richard | Officer | A-Award | A | Stock Option (Right to Buy) | 39,400 | 45.65 | 1.80M | 39,400 | — | ↗ |
| 2023-03-01 | KAKKIS EMIL D | Director / Officer | A-Award | A | Common Stock | 8,716 | 0.00 | — | 569,406 | — | ↗ |
| 2023-03-01 | Huizenga Theodore Alan | Officer | A-Award | A | Stock Option (Right to Buy) | 10,120 | 45.65 | 462.0K | 10,120 | — | ↗ |
| 2023-03-01 | Huang Dennis Karl | Officer | A-Award | A | Stock Option (Right to Buy) | 39,400 | 45.65 | 1.80M | 39,400 | — | ↗ |
| 2023-03-01 | Harris Erik | Officer | A-Award | A | Common Stock | 2,663 | 0.00 | — | 38,823 | — | ↗ |
| 2023-03-01 | Bedrosian Camille L | Officer | S-Sale | D | Common Stock | 3,881 | 45.25 | 175.6K | 46,720 | — | ↗ |
| 2023-02-28 | Huizenga Theodore Alan | Officer | S-Sale | D | Common Stock | 639 | 43.40 | 27.7K | 15,558 | — | ↗ |
| 2022-12-30 | KAKKIS EMIL D | Officer | S-Sale | D | Common Stock | 19,582 | 45.57 | 892.4K | 541,108 | — | ↗ |
| 2022-12-21 | Huizenga Theodore Alan | Officer | S-Sale | D | Common Stock | 2,031 | 43.96 | 89.3K | 16,197 | — | ↗ |
| 2022-10-14 | Dier Mardi | Officer | S-Sale | D | Common Stock | 1,629 | 40.16 | 65.4K | 66,695 | — | ↗ |
| 2022-10-12 | Dier Mardi | Officer | S-Sale | D | Common Stock | 3,484 | 38.22 | 133.2K | 68,324 | — | ↗ |
| 2022-09-01 | Huizenga Theodore Alan | Officer | A-Award | A | Common Stock | 1,000 | 0.00 | — | 18,094 | — | ↗ |
| 2022-06-24 | WELCH DANIEL G | Director | A-Award | A | Stock Option (Right to Buy) | 6,245 | 60.57 | 378.3K | 6,245 | — | ↗ |
| 2022-06-24 | Sanders Corazon (Corsee) D. | Director | A-Award | A | Common Stock | 3,300 | 0.00 | — | 7,195 | — | ↗ |
| 2022-06-24 | SULIMAN SHEHNAAZ | Director | A-Award | A | Common Stock | 3,300 | 0.00 | — | 10,995 | — | ↗ |
| 2022-06-24 | Ray Amrit | Director | A-Award | A | Common Stock | 3,300 | 0.00 | — | 8,420 | — | ↗ |
| 2022-06-24 | NARACHI MICHAEL | Director | A-Award | A | Stock Option (Right to Buy) | 6,245 | 60.57 | 378.3K | 6,245 | — | ↗ |
| 2022-06-24 | Fust Matthew K | Director | A-Award | A | Stock Option (Right to Buy) | 6,245 | 60.57 | 378.3K | 6,245 | — | ↗ |
| 2022-06-24 | Ekman Lars | Director | A-Award | A | Stock Option (Right to Buy) | 6,245 | 60.57 | 378.3K | 6,245 | — | ↗ |
| 2022-06-24 | Dunsire Deborah | Director | A-Award | A | Common Stock | 3,300 | 0.00 | — | 15,870 | — | ↗ |
| 2022-06-19 | Harris Erik | Officer | S-Sale | D | Common Stock | 295 | 54.78 | 16.2K | 36,160 | — | ↗ |
| 2022-04-19 | Ray Amrit | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-04-16 | Huizenga Theodore Alan | Officer | S-Sale | D | Common Stock | 132 | 84.55 | 11.2K | 16,914 | — | ↗ |
| 2022-03-11 | Kassberg Thomas Richard | Officer | S-Sale | D | Common Stock | 10,281 | 67.01 | 688.9K | 227,559 | — | ↗ |
| 2022-03-07 | Parschauer Karah Herdman | Officer | S-Sale | D | Common Stock | 5,140 | 62.95 | 323.6K | 34,438 | — | ↗ |
| 2022-03-04 | Fust Matthew K | Director | M-Exempt | A | Common Stock | 7,500 | 40.37 | 302.8K | 23,195 | — | ↗ |
| 2022-03-01 | Pinion John Richard | Officer | A-Award | A | Common Stock | 14,000 | 0.00 | — | 59,266 | — | ↗ |
| 2022-03-01 | Parschauer Karah Herdman | Officer | A-Award | A | Common Stock | 14,000 | 0.00 | — | 39,578 | — | ↗ |
| 2022-03-01 | Kassberg Thomas Richard | Officer | A-Award | A | Common Stock | 14,000 | 0.00 | — | 227,840 | — | ↗ |
| 2022-03-01 | KAKKIS EMIL D | Director / Officer | A-Award | A | Common Stock | 52,041 | 0.00 | — | 634,226 | — | ↗ |
| 2022-03-01 | Huizenga Theodore Alan | Officer | A-Award | A | Common Stock | 3,710 | 0.00 | — | 17,046 | — | ↗ |
| 2022-03-01 | Huang Dennis Karl | Officer | A-Award | A | Stock Option (Right to Buy) | 24,900 | 0.00 | — | 24,900 | — | ↗ |
| 2022-03-01 | Harris Erik | Officer | S-Sale | D | Common Stock | 2,713 | 66.62 | 180.7K | 22,317 | — | ↗ |
| 2022-03-01 | Dier Mardi | Officer | A-Award | A | Stock Option (Right to Buy) | 24,900 | 0.00 | — | 24,900 | — | ↗ |
| 2022-03-01 | Bedrosian Camille L | Officer | A-Award | A | Common Stock | 14,000 | 0.00 | — | 47,938 | — | ↗ |
| 2022-01-30 | Bedrosian Camille L | Officer | S-Sale | D | Common Stock | 1,657 | 66.30 | 109.9K | 36,759 | — | ↗ |
| 2021-12-31 | Kassberg Thomas Richard | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-31 | KAKKIS EMIL D | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 594,347 | — | ↗ |
| 2021-10-14 | Pinion John Richard | Officer | S-Sale | D | Common Stock | 358 | 81.14 | 29.0K | 49,764 | — | ↗ |
| 2021-10-14 | Parschauer Karah Herdman | Officer | S-Sale | D | Common Stock | 310 | 81.14 | 25.2K | 28,358 | — | ↗ |
| 2021-10-14 | Kassberg Thomas Richard | Officer | S-Sale | D | Common Stock | 286 | 81.14 | 23.2K | 216,266 | — | ↗ |
| 2021-10-14 | KAKKIS EMIL D | Director / Officer | F-InKind | D | Common Stock | 853 | 81.00 | 69.1K | 594,347 | — | ↗ |
| 2021-10-14 | Huizenga Theodore Alan | Officer | S-Sale | D | Common Stock | 140 | 81.14 | 11.4K | 14,072 | — | ↗ |
| 2021-10-14 | Huang Dennis Karl | Officer | S-Sale | D | Common Stock | 358 | 81.14 | 29.0K | 40,148 | — | ↗ |
| 2021-10-14 | Harris Erik | Officer | S-Sale | D | Common Stock | 303 | 81.14 | 24.6K | 25,030 | — | ↗ |
| 2021-10-14 | Dier Mardi | Officer | S-Sale | D | Common Stock | 3,261 | 81.16 | 264.7K | 38,762 | — | ↗ |
| 2021-10-14 | Bedrosian Camille L | Officer | S-Sale | D | Common Stock | 359 | 81.14 | 29.1K | 38,416 | — | ↗ |
| 2021-10-12 | Dier Mardi | Officer | S-Sale | D | Common Stock | 3,477 | 82.79 | 287.9K | 42,023 | — | ↗ |
| 2021-09-30 | Kassberg Thomas Richard | Officer | M-Exempt | A | Common Stock | 109,734 | 0.31 | 34.0K | 216,552 | — | ↗ |
| 2021-09-13 | Huizenga Theodore Alan | Officer | G-Gift | D | Common Stock | 819 | 0.00 | — | 14,212 | — | ↗ |
| 2021-09-08 | Parschauer Karah Herdman | Officer | M-Exempt | D | Stock Option (Right to Buy) | 7,336 | 54.50 | 399.8K | 17,664 | — | ↗ |
| 2021-09-02 | Bedrosian Camille L | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,500 | 55.00 | 137.5K | 53,000 | — | ↗ |
| 2021-09-01 | Bedrosian Camille L | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,500 | 55.00 | 137.5K | 55,500 | — | ↗ |
| 2021-07-06 | Harris Erik | Officer | S-Sale | D | Common Stock | 375 | 91.53 | 34.3K | 25,333 | — | ↗ |
| 2021-06-29 | Sanders Corazon (Corsee) D. | Director | A-Award | A | Common Stock | 3,895 | 0.00 | — | 3,895 | — | ↗ |
| 2021-06-24 | WELCH DANIEL G | Director | A-Award | A | Common Stock | 2,145 | 0.00 | — | 14,445 | — | ↗ |
| 2021-06-24 | SULIMAN SHEHNAAZ | Director | A-Award | A | Common Stock | 2,145 | 0.00 | — | 7,695 | — | ↗ |
| 2021-06-24 | NARACHI MICHAEL | Director | A-Award | A | Common Stock | 2,145 | 0.00 | — | 14,445 | — | ↗ |
| 2021-06-24 | Fust Matthew K | Director | A-Award | A | Common Stock | 2,145 | 0.00 | — | 15,695 | — | ↗ |
| 2021-06-24 | Ekman Lars | Director | A-Award | A | Common Stock | 2,145 | 0.00 | — | 14,445 | — | ↗ |
| 2021-06-24 | Dunsire Deborah | Director | A-Award | A | Common stock | 2,145 | 0.00 | — | 12,570 | — | ↗ |
| 2021-06-24 | Aliski William | Director | A-Award | A | Common Stock | 2,145 | 0.00 | — | 66,849 | — | ↗ |
| 2021-06-21 | Harris Erik | Officer | S-Sale | D | Common Stock | 572 | 94.96 | 54.3K | 25,708 | — | ↗ |
| 2021-06-19 | Harris Erik | Officer | S-Sale | D | Common Stock | 437 | 94.63 | 41.4K | 26,280 | — | ↗ |
| 2021-06-10 | Parschauer Karah Herdman | Officer | S-Sale | D | Common Stock | 1,329 | 100.00 | 132.9K | 28,668 | — | ↗ |
| 2021-05-07 | Harris Erik | Officer | S-Sale | D | Common Stock | 393 | 113.67 | 44.7K | 26,717 | — | ↗ |
| 2021-05-06 | Pinion John Richard | Officer | S-Sale | D | Common Stock | 363 | 113.69 | 41.3K | 50,122 | — | ↗ |
| 2021-05-06 | Parschauer Karah Herdman | Officer | S-Sale | D | Common Stock | 313 | 113.67 | 35.6K | 29,997 | — | ↗ |
| 2021-05-06 | Kassberg Thomas Richard | Officer | S-Sale | D | Common Stock | 363 | 113.69 | 41.3K | 106,818 | — | ↗ |
| 2021-05-06 | KAKKIS EMIL D | Director / Officer | F-InKind | D | Common Stock | 852 | 115.71 | 98.6K | 595,200 | — | ↗ |
| 2021-05-06 | Huizenga Theodore Alan | Officer | S-Sale | D | Common Stock | 142 | 113.67 | 16.1K | 15,031 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-413.4K
Shares Outstanding
98.32M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 861.1K | — | 8.36M | 1.85M | 299.7K | 32.5K | 11.41M | 89.54% | ↗ |
| 2 | 2025 | Erik Harris Chief Commercial Officer and Executive Vice President | 619.7K | — | 2.41M | 712.3K | 291.6K | 14.0K | 4.05M | 77.13% | ↗ |
| 3 | 2025 | Eric Crombez, M.D. Chief Medical Officer and Executive Vice President | 630.2K | — | 2.41M | 712.3K | 238.1K | 14.0K | 4.00M | 77.95% | ↗ |
| 4 | 2025 | Howard Horn Chief Financial Officer, Corporate Strategy and Executive Vice President | 604.4K | — | 2.24M | 663.1K | 227.6K | 14.0K | 3.75M | 77.44% | ↗ |
| 5 | 2025 | Karah Parschauer Chief Legal Officer and Corporate Affairs, Executive Vice President | 585.3K | — | 2.08M | 614.0K | 220.5K | 14.0K | 3.51M | 76.64% | ↗ |
| 6 | 2024 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 856.0K | — | 9.37M | 2.72M | 757.8K | 13.8K | 13.72M | 88.14% | ↗ |
| 7 | 2024 | Eric Crombez, M.D. Chief Medical Officer and Executive Vice President | 591.8K | — | 2.27M | 1.04M | 382.0K | 13.8K | 4.30M | 77.02% | ↗ |
| 8 | 2024 | Howard Horn Chief Financial Officer, Corporate Strategy and Executive Vice President | 590.0K | — | 2.27M | 1.08M | 344.0K | 13.8K | 4.30M | 77.94% | ↗ |
| 9 | 2024 | Erik Harris Chief Commercial Officer and Executive Vice President | 604.2K | — | 2.27M | 1.04M | 367.2K | 13.8K | 4.30M | 77.06% | ↗ |
| 10 | 2024 | John R. Pinion II Chief Quality Officer and Executive Vice President, Translational Sciences | 570.4K | — | 2.08M | 1.12M | 339.8K | 13.8K | 4.13M | 77.63% | ↗ |
| 11 | 2023 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 823.7K | — | 9.46M | 2.16M | 622.7K | 13.2K | 13.08M | 88.84% | ↗ |
| 12 | 2023 | Howard Horn Chief Financial Officer, Corporate Strategy and Executive Vice President | 124.8K | 60.0K | 2.87M | 2.89M | — | — | 5.94M | 96.89% | ↗ |
| 13 | 2023 | Erik Harris Chief Commercial Officer and Executive Vice President | 586.0K | — | 2.17M | 1.02M | 279.6K | 13.2K | 4.07M | 78.40% | ↗ |
| 14 | 2023 | John R. Pinion II Chief Quality Officer and Executive Vice President, Translational Sciences | 552.1K | — | 2.17M | 1.02M | 294.8K | 13.2K | 4.05M | 78.76% | ↗ |
| 15 | 2023 | John R. Pinion II, Chief Quality Officer and Executive Vice President, Translational Sciences | 552.1K | — | 2.17M | 1.02M | 294.8K | 13.2K | 4.05M | 78.76% | ↗ |
| 16 | 2023 | Karah Parschauer Chief Legal Officer & Corporate Affairs and Executive Vice President | 535.2K | — | 2.17M | 1.02M | 298.4K | 13.2K | 4.04M | 79.02% | ↗ |
| 17 | 2022 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 796.2K | — | 7.46M | 3.31M | 558.0K | 12.2K | 12.14M | 88.75% | ↗ |
| 18 | 2022 | Mardi Dier Former Chief Financial Officer and Executive Vice President | 607.3K | — | 2.93M | 892.6K | — | 8.5K | 4.44M | 86.12% | ↗ |
| 19 | 2022 | Camille L. Bedrosian, M.D. Chief Medical Officer and Executive Vice President | 596.0K | — | 2.01M | 892.6K | 246.8K | 12.2K | 3.76M | 77.23% | ↗ |
| 20 | 2022 | Erik Harris Chief Commercial Officer and Executive Vice President | 566.3K | — | 2.01M | 892.6K | 269.7K | 12.2K | 3.75M | 77.37% | ↗ |
| 21 | 2022 | John R. Pinion II Chief Quality Officer and Executive Vice President, Translational Sciences | 533.3K | — | 2.01M | 892.6K | 260.7K | 12.2K | 3.71M | 78.25% | ↗ |
| 22 | 2022 | John R. Pinion II, Chief Quality Officer and Executive Vice President, Translational Sciences | 533.3K | — | 2.01M | 892.6K | 260.7K | 12.2K | 3.71M | 78.25% | ↗ |
| 23 | 2021 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 768.8K | — | 5.41M | 2.84M | 499.1K | 8.7K | 9.52M | 86.59% | ↗ |
| 24 | 2021 | Camille L. Bedrosian, M.D. Chief Medical Officer and Executive Vice President | 567.1K | — | 1.65M | 866.4K | 249.3K | 8.7K | 3.34M | 75.33% | ↗ |
| 25 | 2021 | Mardi Dier Former Chief Financial Officer and Executive Vice President | 561.5K | — | 1.65M | 866.4K | 247.5K | 3.2K | 3.33M | 75.62% | ↗ |
| 26 | 2021 | Mardi Dier Chief Financial Officer and Executive Vice President | 561.5K | — | 1.65M | 866.4K | 247.5K | 3.2K | 3.33M | 75.62% | ↗ |
| 27 | 2021 | Erik Harris Chief Commercial Officer and Executive Vice President | 543.8K | — | 1.65M | 866.4K | 245.0K | 8.7K | 3.32M | 75.96% | ↗ |
| 28 | 2021 | John R. Pinion II, Chief Quality Officer and Executive Vice President, Translational Sciences | 509.9K | — | 1.65M | 866.4K | 224.9K | 8.7K | 3.26M | 77.21% | ↗ |
| 29 | 2020 | Mardi Dier Chief Financial Officer and Executive Vice President | 116.3K | 100.0K | 3.82M | 2.08M | — | — | 6.12M | 96.47% | ↗ |
| 30 | 2020 | Mardi Dier Former Chief Financial Officer and Executive Vice President | 116.3K | 100.0K | 3.82M | 2.08M | — | — | 6.12M | 96.47% | ↗ |
| 31 | 2020 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 759.2K | — | 1.91M | 1.80M | 668.9K | 6.6K | 5.14M | 72.11% | ↗ |
| 32 | 2020 | Erik Harris Chief Commercial Officer and Executive Vice President | 501.2K | — | 723.4K | 707.0K | 292.6K | — | 2.22M | 64.31% | ↗ |
| 33 | 2020 | Camille L. Bedrosian, M.D. Chief Medical Officer and Executive Vice President | 546.7K | — | 695.4K | 674.9K | 297.7K | — | 2.21M | 61.87% | ↗ |
| 34 | 2020 | John R. Pinion II Chief Quality Officer and Executive Vice President, Translational Sciences | 480.1K | — | 723.4K | 707.0K | 267.1K | — | 2.18M | 65.69% | ↗ |
| 35 | 2020 | John R. Pinion II, Chief Quality Officer and Executive Vice President, Translational Sciences | 480.1K | — | 723.4K | 707.0K | 267.1K | — | 2.18M | 65.69% | ↗ |
| 36 | 2020 | Shalini Sharp Former Chief Financial Officer and Executive Vice President | 499.6K | — | — | — | 293.6K | — | 793.2K | 0.00% | ↗ |
| 37 | 2019 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 714.0K | — | 2.70M | 2.65M | 479.8K | 6.6K | 6.55M | 81.68% | ↗ |
| 38 | 2019 | John R. Pinion II Chief Quality Officer and Executive Vice President, Translational Sciences | 447.7K | — | 1.76M | 923.6K | 205.5K | — | 3.33M | 80.40% | ↗ |
| 39 | 2019 | John R. Pinion II, Chief Quality Officer and Executive Vice President, Translational Sciences | 447.7K | — | 1.76M | 923.6K | 205.5K | — | 3.33M | 80.40% | ↗ |
| 40 | 2019 | Shalini Sharp, Chief Financial Officer and Executive Vice President | 484.5K | — | 945.7K | 923.8K | 218.2K | 33.3K | 2.61M | 71.75% | ↗ |
| 41 | 2019 | Shalini Sharp Former Chief Financial Officer and Executive Vice President | 484.5K | — | 945.7K | 923.8K | 218.2K | — | 2.57M | 72.68% | ↗ |
| 42 | 2019 | Camille L. Bedrosian, M.D. Chief Medical Officer and Executive Vice President | 511.2K | — | 878.2K | 863.5K | 230.1K | 2.7K | 2.49M | 70.07% | ↗ |
| 43 | 2019 | Thomas Kassberg Chief Business Officer and Executive Vice President | 474.0K | — | 878.2K | 863.5K | 206.9K | 33.9K | 2.46M | 70.90% | ↗ |
| 44 | 2019 | Erik Harris Chief Commercial Officer and Executive Vice President | 418.1K | — | 691.7K | 962.1K | 201.5K | — | 2.27M | 72.75% | ↗ |
| 45 | 2018 | Wladimir Hogenhuis, M.D. Chief Operating Officer and Executive Vice President | 110.9K | 200.0K | 1.16M | 3.50M | 67.0K | 215.8K | 5.26M | 88.71% | ↗ |
| 46 | 2018 | Camille L. Bedrosian, M.D. Chief Medical Officer and Executive Vice President | 442.3K | 210.0K | 990.0K | 2.91M | 189.3K | 97.6K | 4.84M | 80.58% | ↗ |
| 47 | 2018 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 680.0K | — | 944.4K | 2.75M | 428.4K | 6.6K | 4.81M | 76.83% | ↗ |
| 48 | 2018 | Shalini Sharp, Chief Financial Officer and Executive Vice President | 470.4K | — | 339.0K | 1.02M | 198.7K | 32.8K | 2.06M | 65.94% | ↗ |
| 49 | 2018 | Karah Parschauer General Counsel and Executive Vice President | 386.3K | — | 363.2K | 1.08M | 175.9K | 32.8K | 2.04M | 70.78% | ↗ |
| 50 | 2018 | Shalini Sharp Former Chief Financial Officer and Executive Vice President | 470.4K | — | 339.0K | 1.02M | 198.7K | — | 2.03M | 67.00% | ↗ |
| 51 | 2018 | Thomas Kassberg Chief Business Officer and Executive Vice President | 441.3K | — | 242.2K | 786.7K | 189.6K | 32.9K | 1.69M | 60.78% | ↗ |
| 52 | 2018 | John R. Pinion II, Chief Quality Officer and Executive Vice President, Translational Sciences | 430.3K | — | 217.9K | 728.4K | 188.0K | 36.3K | 1.60M | 59.11% | ↗ |
| 53 | 2018 | John R. Pinion II Chief Quality Officer and Executive Vice President, Translational Sciences | 430.3K | — | 217.9K | 728.4K | 188.0K | — | 1.56M | 60.48% | ↗ |
| 54 | 2018 | Erik Harris Chief Commercial Officer and Executive Vice President | 356.2K | 7.5K | 31.5K | 113.6K | 132.3K | — | 641.1K | 22.64% | ↗ |
| 55 | 2017 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 638.1K | — | 1.32M | 4.30M | 393.0K | 39.2K | 6.68M | 83.99% | ↗ |
| 56 | 2017 | Jayson Dallas, M.D. Chief Commercial Officer and Executive Vice President | 447.5K | 50.0K | 468.4K | 1.65M | 180.4K | 36.3K | 2.83M | 74.80% | ↗ |
| 57 | 2017 | Shalini Sharp, Chief Financial Officer and Executive Vice President | 455.8K | — | 424.0K | 1.54M | 188.3K | 32.7K | 2.64M | 74.39% | ↗ |
| 58 | 2017 | Thomas Kassberg Chief Business Officer and Executive Vice President | 418.4K | — | 335.2K | 1.38M | 168.6K | 32.7K | 2.33M | 73.42% | ↗ |
| 59 | 2017 | Thomas Kassberg Chief Business Officers and Executive Vice President | 418.4K | — | 335.2K | 1.38M | 168.6K | 32.7K | 2.33M | 73.42% | ↗ |
| 60 | 2017 | John R. Pinion II, Chief Quality Officer and Executive Vice President, Translational Sciences | 412.6K | — | 308.6K | 991.2K | 170.5K | 36.5K | 1.92M | 67.72% | ↗ |
| 61 | 2017 | John R. Pinion II Chief Quality | 412.6K | — | 308.6K | 991.2K | 170.5K | 36.5K | 1.92M | 67.72% | ↗ |
| 62 | 2017 | Karah Parschauer General Counsel and Executive Vice President | 357.3K | — | 246.4K | 660.8K | 150.1K | 19.7K | 1.43M | 63.25% | ↗ |
| 63 | 2016 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 567.2K | — | 755.1K | 2.72M | 340.3K | 38.4K | 4.42M | 78.62% | ↗ |
| 64 | 2016 | Karah Parschauer General Counsel and Executive Vice President | 175.0K | 50.0K | 408.8K | 1.97M | 76.5K | 19.5K | 2.70M | 88.12% | ↗ |
| 65 | 2016 | Jayson Dallas, M.D. Chief Commercial Officer and Executive Vice President | 433.0K | 50.0K | 239.9K | 1.32M | 181.9K | 32.4K | 2.26M | 69.18% | ↗ |
| 66 | 2016 | John R. Pinion II Chief Quality | 399.2K | — | 211.7K | 1.22M | 167.7K | 34.6K | 2.04M | 70.45% | ↗ |
| 67 | 2016 | John R. Pinion II Chief Quality Operations Officer and Executive Vice President Analytical Sciences and Research | 399.2K | — | 211.7K | 1.22M | 167.7K | 34.6K | 2.04M | 70.45% | ↗ |
| 68 | 2016 | Shalini Sharp, Chief Financial Officer and Executive Vice President | 441.0K | — | 282.3K | 1.03M | 185.2K | 32.2K | 1.97M | 66.52% | ↗ |
| 69 | 2016 | Thomas Kassberg Chief Business Officers and Executive Vice President | 405.6K | — | 282.3K | 1.03M | 166.3K | 35.6K | 1.92M | 68.29% | ↗ |
| 70 | 2015 | John R. Pinion II Chief Quality Operations Officer and Executive Vice President Analytical Sciences and Research | 171.4K | — | 936.5K | 6.73M | 79.9K | 10.7K | 7.93M | 96.70% | ↗ |
| 71 | 2015 | John R. Pinion II Chief Quality Operations Officer and Senior Vice President Analytical Sciences and Research | 171.4K | — | 936.5K | 6.73M | 79.9K | 10.7K | 7.93M | 96.70% | ↗ |
| 72 | 2015 | John R. Pinion II Chief Quality | 171.4K | — | 936.5K | 6.73M | 79.9K | 10.7K | 7.93M | 96.70% | ↗ |
| 73 | 2015 | Jayson Dallas, M.D. Chief Commercial Officer and Senior Vice President | 164.3K | 100.0K | 1.16M | 6.27M | 74.7K | 40.6K | 7.81M | 95.14% | ↗ |
| 74 | 2015 | Jayson Dallas, M.D. Chief Commercial Officer and Executive Vice President | 164.3K | 100.0K | 1.16M | 6.27M | 74.7K | 40.6K | 7.81M | 95.14% | ↗ |
| 75 | 2015 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 535.0K | — | 967.7K | 3.58M | 280.9K | 38.4K | 5.40M | 84.18% | ↗ |
| 76 | 2015 | Dennis Huang Chief Technical Operations Officer and Senior Vice President | 215.1K | — | 469.7K | 3.44M | 95.8K | 20.4K | 4.24M | 92.19% | ↗ |
| 77 | 2015 | Shalini Sharp, Chief Financial Officer and Senior Vice President | 420.0K | — | 373.5K | 1.38M | 182.7K | 28.1K | 2.38M | 73.52% | ↗ |
| 78 | 2015 | Shalini Sharp, Chief Financial Officer and Executive Vice President | 420.0K | — | 373.5K | 1.38M | 182.7K | 28.1K | 2.38M | 73.52% | ↗ |
| 79 | 2015 | Thomas Kassberg Chief Business Officers and Executive Vice President | 390.0K | — | 373.5K | 1.38M | 165.8K | 31.0K | 2.34M | 74.91% | ↗ |
| 80 | 2014 | Sunil Agarwal, M.D. Senior Vice President and Chief Medical Officer | 150.2K | 100.0K | 1.40M | 5.39M | 164.6K | 7.5K | 7.21M | 94.14% | ↗ |
| 81 | 2014 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 496.9K | — | — | — | 175.0K | 27.2K | 699.0K | 0.00% | ↗ |
| 82 | 2014 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 496.9K | — | — | — | 175.0K | 27.2K | 699.0K | 0.00% | ↗ |
| 83 | 2014 | Shalini Sharp, Chief Financial Officer and Senior Vice President | 350.0K | 30.0K | — | — | 117.6K | 14.5K | 512.1K | 0.00% | ↗ |
| 84 | 2014 | Shalini Sharp, Chief Financial Officer and Executive Vice President | 350.0K | 30.0K | — | — | 117.6K | 14.5K | 512.1K | 0.00% | ↗ |
| 85 | 2014 | Thomas Kassberg Senior Vice President | 362.9K | — | — | — | 112.2K | 16.9K | 491.9K | 0.00% | ↗ |
| 86 | 2013 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 306.0K | — | — | 218.9K | 140.9K | 19.7K | 685.5K | 31.93% | ↗ |
| 87 | 2013 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 306.0K | — | — | 218.9K | 140.9K | 19.7K | 685.5K | 31.93% | ↗ |
| 88 | 2013 | Shalini Sharp, Chief Financial Officer and Senior Vice President | 278.4K | 30.0K | — | 182.4K | 110.2K | 24.2K | 625.2K | 29.17% | ↗ |
| 89 | 2013 | Shalini Sharp Chief Financial Officer and Senior Vice President | 278.4K | 30.0K | — | 182.4K | 110.2K | 24.2K | 625.2K | 29.17% | ↗ |
| 90 | 2013 | Thomas Kassberg Senior Vice President | 289.4K | — | — | 182.4K | 114.3K | 20.4K | 606.5K | 30.07% | ↗ |
| 91 | 2013 | Thomas Kassberg Chief Business Officer | 289.4K | — | — | 182.4K | 114.3K | 20.4K | 606.5K | 30.07% | ↗ |
| 92 | 2013 | Sunil Agarwal, M.D. Senior Vice President and Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 93 | 2012 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 300.2K | — | — | — | 92.1K | 9.1K | 401.4K | 0.00% | ↗ |
| 94 | 2012 | Thomas Kassberg Chief Business Officer | 272.0K | — | — | — | 81.8K | 15.6K | 369.5K | 0.00% | ↗ |
| 95 | 2012 | Shalini Sharp Chief Financial Officer and Senior Vice President | 148.7K | — | — | 90.0K | 51.6K | 13.2K | 303.5K | 29.67% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Emil D. Kakkis | Founder, President, Chief Executive Officer & Director | 1M | — |
| Erik Harris | Executive Vice President & Chief Commercial Officer | 925.3K | male |
| John Richard Pinion | Chief Quality Operations Officer & Executive Vice President of Translational Sciences | 923.9K | male |
| Eric Crombez | Chief Medical Officer & Executive Vice President | 882.4K | — |
| Howard Horn | Executive Vice President of Corporate Strategy & Chief Financial Officer | 846.0K | male |
| Karah Herdman Parschauer | Chief Legal Officer & Executive Vice President of Corporate Affairs | 819.9K | female |
| Eric Olson | Chief Business Officer & Executive Vice President | 714.8K | male |
| Dennis Karl Huang | Chief Technical Operations Officer and Executive Vice President of Gene Therapy Operations | 331.3K | male |
| Vimal Srivastava | Senior Vice President of Business Development & Alliance Management | — | male |
| Alison Skrinar | Vice President of Clinical Outcomes Research and Evaluation | — | — |
| Arjun Natesan | Vice President of Translational Research | — | — |
| Ernie W. Meyer | Chief Human Resources Officer & Executive Vice President | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2026-02-18 | 2026-03-10 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-08-08 | 2025-09-12 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-07-15 | 2025-08-15 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2022-01-21 | 2022-02-08 | Ro Khanna | CA17 | Spouse | Sale | $1,001 - $15,000 | ↗ |
| 2022-01-11 | 2022-02-08 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2021-08-30 | 2021-09-08 | Kurt Schrader | OR05 | — | Purchase | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RARE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
